Stockreport

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials [Yahoo! Finance]

Ernexa Therapeutics Inc.  (ERNA) 
PDF Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer (PROC), anticipated in H2 2026 CAMBRIDGE, Mas [Read more]